Teva: 'Too early' to say whether merger triggers job cuts

Teva Pharmaceutical Industries ($TEVA) says recent reports of up to 1,500 job cuts from the integration of its recent acquisition, Cephalon, "came from unsubstantiated sources." A U.S. spokeswoman told the Daily Local it's too early to know how the merger will affect Teva and Cephalon employees. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.